Australia markets close in 4 hours 5 minutes

BiomX Inc. (PHGE)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
2.4300-0.0400 (-1.62%)
At close: 4:00PM EDT
2.4400 +0.01 (+0.41%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.4700
Open2.6000
Bid2.4000 x 900
Ask2.5000 x 1100
Day's range2.3501 - 2.6000
52-week range2.3500 - 9.0500
Volume254,010
Avg. volume74,839
Market cap68.513M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.4250
Earnings date10 Nov 2021 - 15 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

    BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today that it has entered into an agreement granting Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, a right of first offer to license BiomX’s atopic dermatitis product candidate, BX005, in

  • GlobeNewswire

    BiomX to Present at Upcoming September Investor Conferences

    BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced Jonathan Solomon, Chief Executive Officer, will be presenting at three upcoming virtual investor events in September. Presentation Details: Event: H.C. Wainwright 23rd Annual Global Investments ConferenceDate: Monda

  • GlobeNewswire

    BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update

    Up to $45 Million Secured from Recent Capital Raises Extends Cash Runway to at Least Mid-2023 Expecting Four Clinical Data Readouts by Mid-2022 Company Will Host a Conference Call and Webcast Today at 8:00 am ET NESS ZIONA, Israel, Aug. 16, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, today reported financial results and pro